深圳瑞捷(300977.SZ):與廣聯達簽訂戰略合作框架協議
格隆匯11月17日丨深圳瑞捷(300977.SZ)公佈,2021年11月16日,公司與廣聯達簽訂了《戰略合作框架協議》,出於雙方長遠發展戰略考慮,攜手就國內建築行業材料領域相關業務及產品開展合作,雙方本着“互惠、互利、穩定、恆久、高效、優質”的合作精神,達成戰略合作伙伴關係。
該戰略協議的簽署是公司戰略佈局的重要體現,公司與廣聯達在國內建築材料及行業施工管理相關領域開展合作,有利於雙方實現資源共享和優勢互補,為解決行業痛點提供助力,促進公司運用工程評估大數據優勢為國內建築材料及行業施工管理領域賦能,加快公司在信息化建設、數字化轉型升的戰略佈局,以進一步增強公司綜合競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.